Introduction: In the whole world as well as in the Republic of Croatia, there is an increase in patients suffering from chronic renal disease and anaemia as a consequence of prolonged kidney disease. Research objective: Determine the degree of regulation and control of anemia in patients on hemodialysis depending on the type of erythropoietin Methods: The research was conducted retrospectively for a period of one year (from January 2017 to January 2018). Data were collected from the hospital information system. The study included 54 subjects, divided into three groups depending on the type of erythropoietin they receive and are selected regardless of age, gender and comorbidities Results: Research results show that there are no statistically significant differences between different types of erythropoietin according to the values of erythrocytes, hemoglobin and iron (p> 0.05), but there was a statistically significant difference in ferritin values in subjects who treated anemia with short-term erythropoietin (p <0.05). Furthermore, there was no statistically significant difference in the regulation of anaemia by hemoglobin and ferritin values in subjects on hemodialysis according to the age of the subjects. Also, the difference is not statistically significant in the regulation of anaemia by hemoglobin and ferritin values in subjects on hemodialysis according to gender of subjects. Control of anemia according to the recommended values of hemoglobin between 110 and 120 g/L in the first group is 42% of respondents, in the second group 24% of respondents, and in the third group 31% of respondents. Conclusion: Chronic kidney disease and chronic kidney anemia are a global public health problem, mainly because of an increased morbidity of patients with diabetes and arterial hypertension, and then due to aging of the population. Long-lasting and incorrectly treated anemia leads to heart and blood vessel damage, which is also the most common cause of mortality in these patients. For this reason, it is very important to start treated anemia early to prevent complications and improve the quality of life of these patients.